Crossref
Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?
Onkologie · 2000
DOI: 10.1159/000055041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onkologie, 2000. Verfasst von C.R. Tweedy Jr. und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Jr., C. T., & III, D. A. (2000). Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?. Onkologie. https://doi.org/10.1159/000055041
Vancouver
Jr. CT, III DA. Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?. Onkologie. 2000. doi:10.1159/000055041
BibTeX
@article{Jr2000,
author = {Jr., C.R. Tweedy and III, D.F. Andrews},
title = {Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?},
journal = {Onkologie},
year = {2000},
doi = {10.1159/000055041}
}
EUVIMED